共 25 条
- [11] European Medicines Agency (EMA), EPARS AUTH MED PROD
- [12] Garcia Ramos R., 2011, NEUROLOGIA, V26, P548, DOI [10.1016/j.nrleng.2011.03.00421757265, DOI 10.1016/J.NRLENG.2011.03.00421757265]
- [13] Instituto Nacional de Estadistica (INE), POBL EST ESP
- [14] The decision rules of cost-effectiveness analysis [J]. PHARMACOECONOMICS, 1996, 9 (02) : 113 - 120
- [15] Retigabine as add-on treatment of refractory epilepsy a cost-utility study in a Swedish setting [J]. ACTA NEUROLOGICA SCANDINAVICA, 2013, 127 (06): : 419 - 426
- [16] Magiorkinis E., 2011, HALLMARKS HIST EPILE, P131
- [17] The efficacy and safety of retigabine and other adjunctive treatments for refractory partial epilepsy: A systematic review and indirect comparison [J]. SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2012, 21 (09): : 665 - 678
- [19] Cost-effectiveness analysis in the economic assessment of health interventions [J]. MEDICINA CLINICA, 2004, 122 (13): : 505 - 510
- [20] Sacristán J.A., 2002, Gac Sanit, V16, P334